Results 271 to 280 of about 43,630 (288)
Some of the next articles are maybe not open access.
Live Attenuated Influenza Vaccine in Children
Seminars in Pediatric Infectious Diseases, 2006Live attenuated influenza vaccine (LAIV) offers a novel approach to influenza vaccination and is approved for healthy individuals 5 to 49 years of age. In placebo-controlled studies in children, LAIV was 73 to 93 percent efficacious, and protection lasted more than 12 months.
Edward M. Connor +2 more
openaire +3 more sources
Immunization with Live Attenuated Poliovirus Vaccine
Archives of Pediatrics & Adolescent Medicine, 1961Live attenuated poliovirus vaccine was administered to 400 newborn infants during a three-month period (October, 1959, to January, 1960). This study was designed to obtain information which might provide answers to the following questions. Would the ingestion of larger doses permit enough of the vaccine viruses regularly to pass the "acid barrier" of ...
Marvin S. Eiger +5 more
openaire +2 more sources
Live, Attenuated Rubella-Virus Vaccine
New England Journal of Medicine, 1968HIGH priority is being given in the United States and Europe to the development of an effective live, attenuated rubella (German-measles) virus vaccine.
Robert E. Weibel +3 more
openaire +2 more sources
Live Attenuated Oral Poliovirus Vaccine
Clinical Infectious Diseases, 1984During 1952-1954, some of the first papers were published on the attenuation of wild poliovirus for vaccine purposes. These efforts soon came to fruition , and large-scale field trials were held in many countries under a variety of conditions. Routine use of live oral poliovirus vaccines ( OPV ) was begun in many countries during the spring of 1960 ...
openaire +3 more sources
Live attenuated vaccines for human use
Current Opinion in Biotechnology, 1992Live attenuated vaccines have been successfully used for the prevention of a number of viral and bacterial diseases. Several vaccine strains have been utilized recently as expression vectors for cloned heterologous antigens. Through the use of recombinant DNA technology, candidate vaccine strains and vector systems have been developed and are ...
openaire +3 more sources
Live, Attenuated Mumps-Virus Vaccine
New England Journal of Medicine, 1968Abstract Jeryl-Lynn strain (B level) live, attenuated mumps-virus vaccine was administered to 6283 initially susceptible children and 163 adults, including 132 males. There was no evident clinical reaction to the vaccine either in adults or in children including infants.
Eugene B. Buynak +3 more
openaire +3 more sources
Live Attenuated Varicella-Zoster Vaccine
Clinical Infectious Diseases, 1980Varicella-zoster (VZ) virus causes two diseases, varicella and zoster. Because it was recognized that, after varicella, latent VZ virus persisted in the host and because varicella was thought to be a milde disease, there was little impetus in North America to develop a live VZ vaccine.
openaire +3 more sources
Live Attenuated Vaccines for Pandemic Influenza
2009In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter.
Kanta Subbarao, Grace L. Chen
openaire +3 more sources
A live attenuated human rotavirus vaccine
Drugs of Today, 2007Rotavirus infections are the leading cause of severe gastroenteritis in young children worldwide. This review provides a summary of the development of a live oral rotavirus vaccine, Rotarix (GlaxoSmithKline, Rixensart, Belgium) developed from a single protective G1P[8] human strain.
openaire +2 more sources
Vaccination of Adults With Live Attenuated Mumps Virus Vaccine
JAMA: The Journal of the American Medical Association, 1967A controlled study with live attenuated mumps virus vaccine, B level Jeryl Lynn strain, was conducted on adults without a history of mumps. Altogether, 95 men and women were vaccinated and sera were obtained prior to and 28 days following vaccination for the purpose of measuring initial serologic status for mumps and for ascertaining antibody responses.
Davidson Wl +4 more
openaire +3 more sources